VCBeat Health Contact Us
Home Former Head of Takeda's Oncology Business Unit in China, Huang Haoyu, Departs to Pursue New Opportunities

Former Head of Takeda's Oncology Business Unit in China, Huang Haoyu, Departs to Pursue New Opportunities

Dec 22, 2021 10:36 CST Updated 10:36
Takeda

Biopharmaceutical Manufacturer

On December 21, Takeda sent an email notification that Huang Haoyu, the head of the Oncology Division, decided to leave Takeda China to seek external development opportunities, with the last working day being December 31, 2021. The main products of the Oncology Division now include Enantone, Ninlaro, and Adcetris.

*Disclaimer: This article was written by an author who has settled in Sina Medicine News. The views expressed represent the personal opinions of the author and do not reflect the position of Sina Medicine News.